Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
Posted: December 25, 2024 at 2:51 am
Company Expected Notice for Continued Deficiency and Delist Letter from the Nasdaq Stock Market
Continue reading here:
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
Posted in Global News Feed
Comments Off on HCW Biologics Inc. Received NASDAQ Staff Determination Letter
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
Posted: December 25, 2024 at 2:51 am
WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration
See original here:
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
Posted in Global News Feed
Comments Off on Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
Posted: December 25, 2024 at 2:51 am
– Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators
Originally posted here:
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
Posted in Global News Feed
Comments Off on GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis…
Posted: December 25, 2024 at 2:51 am
WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company, and Tufts Medical Center (“Tufts MC”), a leading academic medical center, today announced the signing of a Patent License Agreement to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis.
Read this article:
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis...
Posted in Global News Feed
Comments Off on Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis…
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Posted: December 25, 2024 at 2:51 am
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function
Read more here:
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Posted in Global News Feed
Comments Off on Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
XBiotech Pauses Rheumatology program
Posted: December 25, 2024 at 2:51 am
Findings from recently completed Rheumatoid Arthritis Study raise questions Findings from recently completed Rheumatoid Arthritis Study raise questions
Read more:
XBiotech Pauses Rheumatology program
Posted in Global News Feed
Comments Off on XBiotech Pauses Rheumatology program
RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program
Posted: December 25, 2024 at 2:51 am
LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI
Here is the original post:
RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program
Posted in Global News Feed
Comments Off on RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
Posted: December 25, 2024 at 2:51 am
PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the next CEO Corner segment has been published on the Company’s website.
Visit link:
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
Posted in Global News Feed
Comments Off on Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
Posted: December 25, 2024 at 2:51 am
WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today the company will host an AI panel during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The panel, titled "AI in Biopharma: Next Frontier of Medical Innovation," will explore the transformative potential of artificial intelligence in the biopharma industry. Panelists will include Dr. David Rhew, Global Chief Medical Officer & VP of Healthcare of Microsoft (Nasdaq: MSFT), Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, and Dr. Sean Tunis, Principal of Rubix Health.
Read the rest here:
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
Posted in Global News Feed
Comments Off on Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
